NCT00344383View on ClinicalTrials.gov

An Open-Label Study Evaluating Breakthrough Bleeding and Spotting With Norgestimate/Ethinyl Estradiol Tablets Administered as an Extended Regimen

PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 30, 2003

Study Completion Date

July 31, 2004

Conditions
Metrorrhagia
Interventions
DRUG

Norgestimate/Ethinyl Estradiol tablet

All Listed Sponsors
lead

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

INDUSTRY

NCT00344383 - An Open-Label Study Evaluating Breakthrough Bleeding and Spotting With Norgestimate/Ethinyl Estradiol Tablets Administered as an Extended Regimen | Biotech Hunter | Biotech Hunter